Loss of response to long-term infliximab therapy in children with Crohn's disease

Pharmaceuticals

Volumn 6, Issue 10, 2013, Pages 1322-1334

  Gouldthorpe, Oliver ^a   Catto Smith, Anthony G ^b,c   Alex, George ^b   Simpson, Di ^b  

^a MONASH UNIVERSITY   (Australia)

^b ROYAL CHILDREN'S HOSPITAL   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Crohn's disease; Growth; Immunomodulator; Infliximab; Paediatrics

Indexed keywords

BUDESONIDE; CORTICOSTEROID; IMMUNOMODULATING AGENT; INFLIXIMAB;

ADOLESCENT; ARTICLE; BODY HEIGHT; BODY WEIGHT; CHILD; COLON DILATATION; COLON PERFORATION; COMMUNITY ACQUIRED PNEUMONIA; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DRUG DOSE REDUCTION; DRUG RESPONSE; FEMALE; HERPES ZOSTER; HUMAN; INFECTION; LONG TERM CARE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PEDIATRIC CROHN DISEASE ACTIVITY INDEX; PERIANAL ABSCESS; PRESCHOOL CHILD; REMISSION; SCHOOL CHILD;

EID: 84885922552     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph6101322     Document Type: Article

References (29)

1. Yang, L.S.; Alex, G.; Catto-Smith, A.G. The use of biological agents in pediatric inflammatory bowel disease. Curr. Opin. Peds. 2012, 24, 609-614.
2. Gouldthorpe, O.; Catto-Smith, A.G.; Alex, G. Biologics in paediatric Crohn's Disease. Gastro Res. Prac 2011, 2011, 287-574.
3. Yanai, H.; Hanauer, S.B. Assessing Response and Loss of Response to Biological Therapies in IBD. Am. J. Gastroenterol. 2011, 106, 685-98.
4. Hyams, J.; Crandall, W.; Kugathasan, S.; Griffiths, A.; Olson, A.; Johanns, J.; Liu, G.; Travers, S.; Heuschkel, R.; Markowitz, J. Induction and Maintenance Infliximab Therapy for the Treatment of Moderate-to-Severe Crohn's Disease in Children. Gastroenterology 2007, 132, 863-873.
5. Hyams, J.S.; Lerer, T.; Griffiths, A.; Pfefferkorn, M.; Kugathasan, S.; Evans, J.; Otley, A.; Carvalho, R.; Mack, D.; Bousvaros, A. Long-term outcome of maintenance infliximab therapy in children with Crohn's disease. Inflamm. Bowel Dis. 2009, 15, 816-822.
6. Ruemmele, F.M.; Lachaux, A.; Cézard, J.P.; Morali, A.; Maurage, C.; Giniès, J.L.; Viola, S.; Goulet, O.; Lamireau, T.; Scaillon, M. Efficacy of infliximab in pediatric Crohn's disease: A randomized multicenter open-label trial comparing scheduled to on demand maintenance therapy. Inflamm. Bowel Dis. 2009, 15, 388-394.
7. Colombel, J.F.; Sandborn, W.J.; Reinisch, W.; Mantzaris, G.J.; Kornbluth, A.; Rachmilewitz, D.; Lichtiger, S.; D'Haens, G.; Diamond, R.H.; Broussard, D.L. Infliximab, azathioprine, or combination therapy for Crohn's disease. N. Engl. J. Med. 2010, 362, 1383-1395.
8. Kotlyar, D.S.; Osterman, M.T.; Diamond, R.H.; Porter, D.; Blonski, W.C.; Wasik, M.; Sampat, S.; Mendizabal, M.; Lin, M.V.; Lichtenstein, G.R. A systematic review of factors that contribute to Hepatosplenic T-Cell Lymphoma in patients with Inflammatory Bowel Disease. Clin. Gastroenterol. Hepatol. 2011, 9, 36-41.
9. Ullman, T.A.; Itzkowitz, S.H. Intestinal inflammation and cancer. Gastroenterology 2011, 140, 1807-1816.
10. Steenholdt, C.; Brynskov, J.; Thomsen, O.O.; Munck, L.K.; Fallingborg, J.; Christensen, L.A.; Pedersen, G.; Kjeldsen, J.; Jacobsen, B.A.; Oxholm, A.S. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: A randomised, controlled trial. Gut 2013, doi:10.1136/gutjnl-2013-305279.
11. Connell, W.; Andrews, J.M.; Brown, S.; Sparrow, M. Practical guidelines for treating inflammatory bowel disease safely with anti-tumour necrosis factor therapy in Australia. Intern. Med. J. 2010, 40, 139-149.
12. Motil, K.J.; Grand, R.J.; Davis-Kraft, L.; Ferlic, L.L.; Smith, E.O. Growth failure in children with inflammatory bowel disease: A prospective study. Gastroenterology 1993, 105, 681-691.
13. Sawczenko, A.; Sandhu, B.K. Presenting features of inflammatory bowel disease in Great Britain and Ireland. Arch. Dis. Child. 2003; 88, 995-1000.
14. Sawczenko, A.; Ballinger, A.B.; Savage, M.O.; Sanderson, I.R. Clinical features affecting final adult height in patients with pediatric-onset Crohn's disease. Pediatrics 2006, 118, 124-129.
15. MacRae, V.E.; Wong, S.C.; Farquharson, C.; Ahmed, S.F. Cytokine actions in growth disorders associated with pediatric chronic inflammatory diseases (review). Int. J. Mol. Med. 2006, 18, 1011-1018.
16. Wong, S.C.; Smyth, A.; McNeill, E.; Galloway, P.J.; Hassan, K.; McGrogan, P.; Ahmed, S.F. The growth hormone insulin-like growth factor 1 axis in children and adolescents with inflammatory bowel disease and growth retardation. Clin. Endocrinol. (Oxf.) 2010, 73, 220-228.
17. MacRae, V.E.; Farquharson, C.; Ahmed, S.F. The restricted potential for recovery of growth plate chondrogenesis and longitudinal bone growth following exposure to pro-inflammatory cytokines. J. Endocrinol. 2006, 189, 319-328.
18. Pfefferkorn, M.; Burke, G.; Griffiths, A.; Markowitz, J.; Rosh, J.; Mack, D.; Otley, A.; Kugathasan, S.; Evans, J.; Bousvaros, A. Growth abnormalities persist in newly diagnosed children with Crohn disease despite current treatment paradigms. J. Pediatr. Gastroenterol. Nutr. 2009, 48, 168-174.
19. Walters, T.D.; Gilman, A.R.; Griffiths, A.M. Linear growth improves during infliximab therapy in children with chronically active severe Crohn's disease. Inflamm. Bowel Dis. 2007, 13, 424-430.
20. Van Assche, G.; Dignass, A.; Panes, J.; Beaugerie, L.; Karagiannis, J.; Allez, M.; Ochsenkuhn, T.; Orchard, T.; Rogler, G.; Louis, E. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. J. Crohns. Colitis 2010, 4, 7-27.
21. Satsangi, J.; Silverberg, M.S.; Vermeire, S.; Colombel, J.F. The Montreal classification of inflammatory bowel disease: Controversies, consensus, and implications. Gut 2006, 55, 749-753.
22. Available online: http://pbs.gov.au/medicine/item/4284L-5753T-5754W-5755X-5756Y-5757B-5758C-6397Q-6448J-6496X-9612X-9613Y-9617E-9654D-9674E (accessed on 2 October 2013).
23. Van Assche, G.; Magdelaine-Beuzelin, C.; D'Haens, G.; Baert, F.; Noman, M.; Vermeire, S.; Ternant, D.; Watier, H.; Paintaud, G.; Rutgeerts, P. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: A randomized trial. Gastroenterology 2008, 134, 1861-1868.
24. Turner, D.; Griffiths, A.M.; Walters, T.D.; Seah, T.; Markowitz, J.; Pfefferkorn, M.; Keljo, D.; Otley, A.; Leleiko, N.S.; Mack, D. Appraisal of the pediatric Crohn's disease activity index on four prospectively collected datasets: recommended cutoff values and clinimetric properties. Am. J. Gastroenterol. 2010, 105, 2085-2092.
25. Rosh, J.R.; Lerer, T.; Markowitz, J.; Goli, S.R.; Mamula, P.; Noe, J.D.; Pfefferkorn, M.D.; Kelleher, K.T.; Griffiths, A.M.; Kugathasan, S. Retrospective evaluation of the safety and effect of adalimumab therapy (RESEAT) in pediatric Crohn's disease. Am. J. Gastroenterol. 2009, 104, 3042-3049.
26. Russell, R.K.; Wilson, M.L.; Loganathan, S.; Bourke, B.; Kiparissi, F.; Mahdi, G.; Torrente, F.; Rodrigues, A.; Davies, I.; Thomas, A. A British Society of Paediatric Gastroenterology, Hepatology and Nutrition survey of the effectiveness and safety of adalimumab in children with inflammatory bowel disease. Aliment. Pharmacol. Ther. 2011, 33, 946-953.
27. Malik, S.; Wong, S.; Bishop, J.; Hassan, K.; McGrogan, P.; Ahmed, S.; Russell, R. Improvement in growth of children with crohn disease following anti-TNF-α therapy can be independent of pubertal progress and glucocorticoid reduction. J. Pediatr. Gastroenterol. Nutr. 2011, 52, 31-37.
28. Van Limbergen, J.; Russell, R.K.; Drummond, H.E.; Aldhous, M.C.; Round, N.K.; Nimmo, E.R.; Smith, L.; Gillett, P.M.; McGrogan, P.; Weaver, L.T. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology 2008, 135, 1114-1122.
29. Vernier-Massouille, G.; Balde, M.; Salleron, J.; Turck, D.; Dupas, J.L.; Mouterde, O.; Merle, V.; Salomez, J.L.; Branche, J.; Marti, R. Natural history of pediatric Crohn's disease: A population-based cohort study. Gastroenterology 2008, 135, 1106-1113.